Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18659799 | 0.85 | KDM4E (0.46) | ALDH1A1MAPK1LMNAKMT2AHTT | |
| SCHEMBL28060100 | 0.85 | KDM4E (0.63) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL17078007 | 0.83 | ELANE (0.38) | ALDH1A1MAPK1GAAKMT2ACA1 | |
| SCHEMBL20501206 | 0.81 | KMT2A (0.41) | ALDH1A1MAPK1GAALMNAKMT2A | |
| SCHEMBL21798567 | 0.81 | KDM4E (0.53) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL19194087 | 0.77 | KDM4E (0.59) | ALDH1A1LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21798595 | 0.77 | KDM4E (0.49) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL20501207 | 0.77 | KMT2A (0.41) | ALDH1A1MAPK1GAALMNAKMT2A | |
| SCHEMBL29569867 | 0.77 | KMT2A (0.41) | ALDH1A1MAPK1GAALMNAKMT2A | |
| SCHEMBL1369472 | 0.76 | NR4A2 (0.48) | ALDH1A1GAAMAPTSMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230365519-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365519-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022074588-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-10844027-B2 | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190047970-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AS MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2018170275-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | OPRD1, OPRM1, OPRK1 | ALDH1A1 577/4885MAPK1 1666/4885GAA 2298/4885 |
| US-20190047970-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AS MU-OPIOID RECEPTOR AGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 1051/4885MAPK1 3213/4885GAA 3891/4885 |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | OPRD1, OPRM1, OPRK1 | ALDH1A1 577/4885MAPK1 1666/4885GAA 2298/4885 |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, KMT5A, CDKL1 | ALDH1A1 1878/4885MAPK1 1071/4885GAA 2250/4885 |
| US-20230365519-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, CDKL1, H1-5 | ALDH1A1 2675/4885MAPK1 1887/4885GAA 2550/4885 |
| US-10844027-B2 | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists | OPRL1, OPRM1, OPRK1 | ALDH1A1 1051/4885MAPK1 3213/4885GAA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.